Is Novartis AG a good investment? Novartis AG (NOTA.F) is currently trading at 125.00 EUR.
In terms of valuation, the stock trades at a P/E ratio of 21.01. This valuation is generally in line with the broader market.
For income investors, Novartis AG pays a dividend yield of 3.43%. With a payout ratio of 68%, the dividend appears sustainable.
Yes, it pays an annual dividend of 4.15 EUR (3.43% yield).
Novartis AG is classified as a Stock. You can compare it against 10 other assets in the "Related Symbols" list on this page.
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
3.43% (5y avg: 3.54%)
4.15 EUR
March 11, 2026
67.91%
| Year | Total Dividends |
|---|---|
| 2027 | 4.33 EUR |
| March 4, 2027 (estimated) | 4.3276 |
| 2026 | 4.12 EUR |
| March 11, 2026 | 4.1248 |
| 2025 | 3.42 EUR |
| March 12, 2025 | 3.4157 |
| 2024 | 3.20 EUR |
| March 7, 2024 | 3.1981 |
| 2023 | 2.99 EUR |
| March 9, 2023 | 2.9921 |
| 2022 | 2.84 EUR |
| March 8, 2022 | 2.8438 |
| 2021 | 2.74 EUR |
| March 4, 2021 | 2.7358 |
| 2020 | 2.64 EUR |
| March 3, 2020 | 2.6403 |
| 2019 | 2.42 EUR |
| March 4, 2019 | 2.4237 |
| 2018 | 2.51 EUR |
| March 6, 2018 | 2.5113 |
| 2017 | 2.32 EUR |
| March 1, 2017 | 2.3242 |
| 2016 | 2.32 EUR |
| Feb. 24, 2016 | 2.3244 |
| 2015 | 2.28 EUR |
| March 2, 2015 | 2.2799 |
| 2014 | 2.36 EUR |
| Feb. 27, 2014 | 2.3602 |
| 2013 | 2.16 EUR |
| Feb. 26, 2013 | 2.1636 |
| 2012 | 2.12 EUR |
| Feb. 27, 2012 | 2.1227 |
| 2011 | 2.02 EUR |
| Feb. 24, 2011 | 2.0211 |
Yearly aggregated dividends
|
Novartis AG
Mar 11, 2026 Paid
Dividend
4.124793 EUR |
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion